Merck-Pfizer Avelumab on FDA Fast Track

After previously receiving Orphan Drug status for avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody to treat the rare and aggressive skin cancer Merkel cell carcinoma (MCC), Merck KGaA and Pfizer have now been awarded Fast Track status from the US Food and Drug Administration (FDA).

Fast Track designation is designed to facilitate the development and expedite the review of drugs to treat serious conditions and address an unmet medical need. Such products are eligible for accelerated approval and priority review, if the relevant criteria are met, and rolling FDA review of marketing applications.

The clinical development program for avelumab launched by the global strategic immuno-oncology alliance between the German and US drugmakers now includes more than 1,000 patients who have been treated across more than 15 tumor types. These include breast cancer, gastric/gastroesophageal cancer, head and neck cancer, MCC, mesothelioma, melanoma, non-small cell lung cancer, ovarian cancer, renal cell carcinoma and urothelial cancer.

Avelumab was initially discovered and developed by Merck. Along with jointly developing and commercializing the cancer treatment, the two companies’ alliance will also advance Pfizer’s PD-1 antibody.

Altogether, Merck and Pfizer plan to collaborate on up to 20 high priority immuno-oncology clinical development programs, including combination trials. Many of these are expected to commence before the end of this year.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.